Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma
Abstract Immune checkpoint inhibitor (ICI)‐based therapies have shown promising advances for the first‐line treatment of advanced or metastatic esophageal cancer (EC). However, few studies concerning the identification of patients who achieve durable response from ICIs have been previously reported....
Main Authors: | Dongyang Yang, Fei Xu, Ying Li, Xiaorong Lai, Bohong Xian, Pengli Yu, Rongrong Chen, Zijun Li, Dong Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-10-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14610 |
Similar Items
-
Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials
by: Zhen Zhang, et al.
Published: (2023-06-01) -
Prognostic value of inflammatory nutritional scores in locally advanced esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multicenter study in China
by: Jinxin Xu, et al.
Published: (2024-02-01) -
Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
by: Shixian Liu, et al.
Published: (2023-03-01) -
Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study
by: Shu-Han Xie, et al.
Published: (2024-02-01) -
Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma
by: Ye Wang, et al.
Published: (2024-04-01)